 WALTHAM, Mass., Aug. 08, 2022 GLOBE NEWSWIRE -- Viridian Therapeutics, Inc. NASDAQ: VRDN, a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the second quarter ended June 30, 2022, before the financial markets open on Monday, August 15, 2022. 